p53-dependent p21 induction following γ-irradiation without concomitant p53 induction in a human peripheral neuroepithelioma cell line

Cancer Research

Volumn 57, Issue 14, 1997, Pages 2986-2992

  Isaacs, Jennifer S ^a   Chiao, Chia ^b   Merrick, B Alex ^b   Selkirk, James K ^b   Barrett, J Carl ^b   Weissman, Bernard E ^a,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN P21; PROTEIN P53;

ARTICLE; CANCER CELL CULTURE; DNA DAMAGE; GAMMA IRRADIATION; GENE EXPRESSION REGULATION; GENE INDUCTION; HUMAN; HUMAN CELL; NEUROEPITHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BIOLOGICAL TRANSPORT; CELL NUCLEUS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; GAMMA RAYS; HUMANS; NEUROECTODERMAL TUMORS, PRIMITIVE, PERIPHERAL; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030871776     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Yin, Y., Tainsky, M. A., Bischoff, F. Z., Strong, L. C., and Wahl, G. M. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell, 70: 937-948, 1992.
2. Livingstone, L., White, A., Sprouse, J., Livanos, E., Jacks, T., and Tlsty, T. D. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell, 70: 923-935, 1992.
3. Harvey, M., Sands, A. T., Weiss, R. S., Hegi, M. E., Wiseman, R. W., Pantazis, P., Giovanella, B. C., Tainsky, M. A., Bradley, A., and Donehower, E. A. In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene, 8: 2457-2467, 1993.
4. Hollenstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Washington DC), 253: 49-53, 1991.
5. Yew, P. R., and Berk, A. J. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature (Lond.), 357: 82-85, 1992.
6. Debbas, M., and White, E. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes & Dev., 7: 535-545, 1993.
7. Sarnow, P., Ho, Y. S., Williams, J., and Levine, A. J. Adenovirus E1B 58-kDa tumor antigen and SV40 large tumor antigen are physically associated with the same 54-kDa cellular protein. Cell, 28: 387-394, 1982.
8. Werness, B. A., Levine, A. J., and Howley, P. M. Association of human papillomavirus types 16 and 18 proteins with p53. Science (Washington DC), 248: 76-79, 1990.
9. Chen, C-Y., Oliner, J. D., Zhan, Q., Fornace, A. J., Jr., Vogelstein, B., and Kastan, M. B. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc. Natl. Acad. Sci. USA, 91: 2684-2688, 1994.
10. Maheswaran, S., Englert, C., Bennett, P., Heinrich, G., and Haber, D. A. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes & Dev., 9: 2143-2156, 1995.
11. 1 checkpoint after DNA damage. Mol. Cell. Biol., 16: 1126-1137, 1996.
12. Knippschild, U., Oren, M., and Deppert, W. Abrogation of wild-type p53-mediated growth inhibition by nuclear exclusion. Oncogene, 12: 1755-1765, 1996.
13. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D., Parsons, R., Trent, J. M., Lin, D., Mercer, E., Kinzler, K. W., and Vogelstein, B. WAF 1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
14. 1 cyclin-dependent kinases. Cell, 75: 805-816, 1993.
15. Xiong, Y., Hannon, H., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366: 701-704, 1993.
16. Zhan, Q., Carrier, F., and Fornace, A. J., Jr. Induction of cellular p53 activity by DNA-damaging agents and growth arrest. Mol. Cell. Biol., 13: 4242-4250, 1993.
17. Shaulsky, G., Goldfinger, N., Ben-ze'ev, A., and Rotter, V. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol. Cell. Biol., 10: 6565-6577, 1990.
18. Yamaizumi, M., and Sugano, T. UV-induced nuclear accumulation of p53 is evoked through DNA damage of actively transcribed genes independent of the cell cycle. Oncogene, 9: 2775-2784, 1994.
19. Isaacs, J. S., Chen, P., Garza, A., Hansen, M. F., Barrett, J. C., and Weissman, B. E. Failure of HPV E6 to rapidly degrade p53 in human HeLa × PNET cell hybrids. Oncogene, 14: 1669-1678, 1997.
20. Giard, D. J., Aaronson, S. A., Todaro, G. J., Arnstein, P., Dosik, H., and Parks, W. P. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J. Natl. Cancer Inst. 51: 1417-1423, 1974.
21. Chen, P-L., Chen, Y., Bookstein, R., and Lee, W-H. Genetic mechanisms of tumor suppression by the human p53 gene. Science (Washington DC), 250: 1576-1580, 1990.
22. Lee, W-H., Shew, J-Y., Hong, F. D., Sery, T. W., Donoso, L. A., Young, L-J., Bookstein, R., and Lee, E. Y-H. P. The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity. Nature (Lond.), 329: 692-695, 1987.
23. Soong, H. K., Dass, B., and Lee, B. Distribution of cyloplasmic microtubules in migrating conical epithelial cells: an immunofluorescence study. Cornea, 7: 267-272, 1988.
24. Chen, Y., Chen, P-L., Arnaiz, N., Goodrich, D., and Lee, W-H. Expression of wild-type p53 in human A673 cells suppresses tumorigenicity but not growth rate. Oncogene, 6: 1799-1805, 1991.
25. + p53 conformation. Oncogene, 8: 2847-2851, 1993.
26. CIP/Waf1 expression in human breast epithelial cells. Oneogene, 11: 253-261, 1995.
27. Kern, S. E., Pientenpol, J. A., Thiagalingam, S., Seymour, A., Kinzler, K. W., and Vogelstein, B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science (Washington DC), 256: 827-830, 1992.
28. Bargonetti, J., Reynisdottir, I., Friedman, P. N., and Prives, C. Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. Genes & Dev., 6: 1886-1898, 1992.
29. Johnson, M., Dimitrov, D., Vojta, P. J., Barrett, J. C., Noda, A., Pereira-Smith, O. M., and Smith, J. R. Evidence for a p53-independent pathway for up-regulation of SDI1/CIP1/WAF1/p21 RNA. Mol. Carcinog., 11: 59-64, 1994.
30. Jiang, H., Lin, J., Su, Z-z., Collart, F. R., Huberman, E., and Fisher, P. B. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF/CIP, expression in the absence of p53. Oncogene, 9: 3397-3406, 1994.
31. WAF/CIP1/SDI1 is elevated through a p53-independent pathway by mimosine. Cell Growth & Differ., 7: 893-901, 1996.
32. Akashi, M., Hachiya, M., Osawa, Y., Spirin, K., Suzuki, G., and Koeffler, H. P. Irradiation induces WAF1 expression through a p53-independent pathway in KG-1 cells. J. Biol. Chem., 270: 19181-19187, 1995.
33. Butz, K., Shahabeddin, L., Geisen, C., Spilovsky, D., Ullman, A., and Hoppe-Seyler, F. Functional p53 protein in human papillomavirus-positive cancer cells. Oncogene, 10: 927-936, 1995.
34. 1 arrest by expression of the wild-type p53 gene in small cell lung carcinoma. Cell Growth & Differ., 7: 879-886, 1996.
35. 1 arrest. Proc. Natl. Acad. Sci. USA, 91: 10079-10083, 1994.
36. 1-S boundary after irradiation. Oncogene, 12: 875-882, 1996.
37. Kato, J-y., Matsushime, H., Hiebert, S. W., Ewen, M., and Sherr, C. J. Direct binding of cyclin D to the retinoblasloma gene product (pRb), and pRb phosphorylation by the cyclin D-dependent kinase CD4. Genes & Dev., 7: 331-342, 1993.
38. 1 cyclin-Cdk protein kinase activity, is related to p21. Cell, 78: 67-74, 1994.
39. Coats, S., Flanagan, W. M., Nourse, J., and Roberts, J. M. Requirement for p27Kip1 for restriction point control of the fibroblast cell cycle. Science (Washington DC), 272: 877-880, 1996.
40. Serrano, M., Hannon, G. J., and Beach, D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.), 366: 704-707, 1993.
41. Xiong, Y., Zhang, H., and Beach, D. Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes & Dev., 7: 1572-1583, 1993.
42. Demers, G. W., Foster, S. A., Halbert, C. L., and Galloway, B. Growth arrest by induction of p53 in DNA-damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc. Natl. Acad. Sci. USA. 91: 4382-4386, 1994.
43. Hickman, E. S., Picksley, S. M., and Vousden, K. H. Cells expressing HPV16 E7 continue cell cycle progression following DNA damage-induced p53 activation. Oncogene, 9: 2177-2181, 1994.
44. Maltzman, W., and Czyzk, L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol., 4: 1689-1694, 1984.
45. Kastan, M. B., Onyekwere, O., Estabrooks, L. L., and Wilson, S. J. Participation of p53 in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
46. Hall, P. A., McKee, P. H., Menage, H. d. P., Dover, R., and Lane, D. P. High levels of p53 protein in UV-irradiated normal human skin. Oncogene, 8: 203-207, 1993.
47. Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fornace, A. J., Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 71: 587-597, 1992.
48. Fiscella, M., Ullrich, S. J., Zambrano, N., Shields, M., Lin, D., Lees-Miller, S. P., Anderson, C. W., Mercer, W. E., and Appella, E. Mutation of the serine 15 phosphorylation site of human p53 reduces the ability of p53 to inhibit cell cycle progression. Oncogene, 8: 1519-1528, 1993.
49. Girinsky, T., Koumenis, C., Graeber, T. G., Peehl, D. M., and Giaccia, A. J. Attenuated response of p53 and p21 in primary cultures of human prostatic epithelial cells exposed to DNA-damaging agents. Cancer Res., 55: 3726-3731, 1995.
50. Hecker, D., Page, G., Lohrum, M., Weiland, S., and Scheidtmann, H. Complex regulation of the DNA-binding activity of p53 phosphorylation: differential effects of individual phosphorylation sites on the interaction with different binding motifs. Oncogene, 12: 953-961, 1996.
51. Milne, D. M., Palmer, R. H., Campbell, D. G., and Meek, D. W. Phosphorylation of the p53 tumour suppressor protein at three N-terminal sites by a novel casein kinase I-like enzyme. Oncogene, 7: 1361-1369, 1992.
52. Meek, D. W., Simon, S., Kikkawa, U., and Eckhart, W. The p53 tumour suppressor protein is phosphorylated at serine 389 by casein kinase II. EMBO J., 9: 3253-3260, 1990.
53. Hupp, T. R., Meek, D. W., Midgley, C. A., and Lane, D. P. Regulation of the specific DNA binding function of p53. Cell, 71: 875-886, 1992.
54. Bischoff, J. R., Friedman, P. N., Marshak, D. R., Prives, C., and Beach, D. Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proc. Natl. Acad. Sci. USA, 87: 4766-4770, 1990.
55. Milner, J., Cook, A., and Mason, J. p53 is associated with p34 cdc2 in transformed cells. EMBO J., 9: 2885-2889, 1990.
56. Lees-Miller, S., Sagakuchi, K., Ullrich, S. J., Appella, E., and Anderson, C. W. Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. Mol. Cell. Biol., 12: 5041-5049, 1992.
57. Milne, D. M., Campbell, D. G., Candwell, F. B., and Meek, D. W. Phosphorylation of the tumor suppressor protein p53 by mitogen-activated protein kinases. J. Biol. Chem., 269: 9253-9260, 1994.
58. Baudier, J., Delphin, C., Grunwald, D., Khochbin, S., and Lawrence, J. J. Characterization of the tumor suppressor protein p53 as a protein kinase C substrate and a S100b-binding protein. Proc. Natl. Acad. Sci. USA, 87: 4766-4770, 1992.
59. Jamal, S., and Ziff, E. B. Raf phosphorylates p53 in vitro and potentiates p53-dependent transcriptional activation in vivo. Oncogene, 10: 2095-2101, 1995.
60. Muller, E., and Scheidtmann, K. H. Purification and characterization of a protein kinase which is activated by SV40 large T-antigen and phosphorylates the tumor suppressor protein p53. Oncogene, 10: 1175-1185, 1995.
61. Milne, D. M., Campbell, L., Campbell, D. G., and Meek, D. W. p53 is phosphorylated in vitro and in vivo by an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase. JNK1. J. Biol. Chem., 270: 5511-5518, 1995.
62. 2 terminus-targeted protein kinase activity is stimulated in response to wild-type p53 and DNA damage. Oncogene, 13: 1387-1393, 1996.
63. Selkirk, J. K., Merrick, B. A., Stackhouse, L., and He, C. Multiple p53 protein isoforms and formation of oligomeric complexes with heat shock proteins Hsp 70 and Hsp 90 in the human mammary tumor T47D cell line. Appl. Theor. Electro., 4: 11-18, 1994.
64. Ramaprasad, S., and Maxwell, S. A. A cellular protein activates the sequence-specific DNA binding of p53 by interacting with the central conserved region. Oncogene, 12: 193-200, 1996.
65. Kumar, M. G., and Spandau, D. F. p53-binding proteins in squamous cell carcinoma and normal human keratinocytes. Cell Growth & Differ., 6: 1601-1608, 1995.
66. Tanaka, N., Ishihara, M., and Lamphier, M. S. Cooperation of the tumor suppressors IRF-1 and p53 in response to DNA damage. Nature (Lond.), 382: 816-818, 1996.
67. Vojtesek, B., and Lane, D. P. Regulation of p53 protein expression in human breast cancer cell lines. J. Cell Sci., 105: 607-612, 1993.
68. Niewolik, D., Vojtesek, B., and Kovarik, J. p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence. Oncogene, 10: 881-890, 1995.
69. Forrester, K., Lupold, S. E., Ott, V. L., Chay, C. H., Band, V., Wang, X. W., and Harris, C. C. Effects of p53 mutants on wild-type p53-mediated transactivation are cell cycle-dependent. Oncogene, 10: 2103-2111, 1995.